louisiana semaglutide gastrointestinal obstruction lawsuit gi class action glp-1 gastric intestinal obstruction attorney in louisiana Ozempic GLP-1 & glp-1 diarrhea attorney at law

Pharmacovigilance and signal detection FAERS semaglutide disproportionality (broad): A FAERS-based disproportionality analysis of semaglutide reports through mid-2023 identified multiple unexpected adverse event signals and explicitly notes that some signals were not mentioned in the drug insert, including polycystic ovaries. The analysis highlights typical spontaneous-reporting limitations (missing age, outcome data)

One small study suggested this form could improve sprinting ability in well-trained soccer players

Risks include melanoma (skin cancer) and long, painful erections, says the FDA

What to Expect from Non-Surgical Skin Tightening Results Setting realistic expectations is crucial for satisfaction with any cosmetic treatment

Rajilic-Stojanovic M, Heilig HG, Molenaar D, Kajander K, Surakka A, Smidt H, et al